期刊文献+

Combretastatin A-4及其类似物构效关系研究进展

Research progress in the structure-activity relationship of combretastatin A-4 and its analogues
原文传递
导出
摘要 Combretastatin A-4(CA-4)是一个天然的秋水仙碱结合位点抑制剂,其突出的生物活性引起人们的高度关注,近年来,不断有结构多样的类似物被发现。这些类似物主要是针对CA-4的A环、B环和顺式双键的结构修饰,其中,以用单原子或环状结构替代顺式双键进而保持A/B环具有合适的空间距离和角度为主。本文对CA-4及其类似物构效关系的研究进行简单概述。 Combretastatin A-4 (CA-4), as a natural colchicine binding site inhibitor, has prominent biological activity, which has aroused widespread attention. In last two decades, a large number of analogues of CA-4 have been reported with significant structural diversity. These analogues are mainly about the modifications of the ring A, ring B and cis-double bond. Among them, replacement the cis-double bond with single atom or cyclic structure to make sure the suitable distance between ring A and ring B is a simple and effective stratagy of modifications about CA-4. A synopsis of recent advances in research of structure-activity relationship of CA-4 and its analogues were reviewed.
作者 李晓娜 田海秋 张为革 LI Xiao-na TIAN Hai-qiu ZHANG Wei-ge(Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University), Ministry of Education, Shenyang 110016, China)
出处 《中国药物化学杂志》 CAS CSCD 2017年第5期388-399,共12页 Chinese Journal of Medicinal Chemistry
关键词 COMBRETASTATIN A-4类似物 秋水仙碱结合位点抑制剂 构效关系 研究进展 combretastatin A-4 analogues colchicine binding site inhibitors structure-activity relationship research advances
  • 相关文献

参考文献1

二级参考文献33

  • 1Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumor therapy [J]. Br J Cancer, 1982, 45: 136-139.
  • 2Patherson DM, Rustin GJ. Vascular damaging agents [J]. Clin Oncol (R Coil Radiol), 2007, 19:443-456.
  • 3Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of vascular-targeted therapies [J]. Clin Cancer Res, 2005, 11: 416-420.
  • 4Chaplin D J, Hill SA. The development of combretastatin A4 phosphate as a vascular targeting agent [J]. Int J Radiat Oneol Biol Phys, 2002, 54: 1491-1496.
  • 5Pettit GR, Rhodes MR, Herald DL, et al. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41 [J]. J Med Chem, 2005, 48: 4087-4099.
  • 6Thorpe PE. Vascular targeting agents as cancer therapeutics [J]. Clin Cancer Res, 2004, 10: 415-427.
  • 7Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents [J]. Bioassays, 1991, 13: 31-36.
  • 8Sun CM, Lin LG, Yu H J, et al. Synthesis and cytotoxic activities of 4, 5-diarylisoxazoles [J]. Bioorg Med Chem Lett, 2007, 17: 1078-1081.
  • 9Chaplin D J, Horsman MR. The influence of tumour temperature on ischemia-induced cell death: potential implications for the evaluation of vascular mediated therapies [J]. Radiother Oncol, 1994, 30: 59-65.
  • 10Robinson SP, Mcintyre D J, Checkley D, et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging [J]. Br J Cancer, 2003, 88: 1592-1597.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部